Lunx is a superior molecular marker for detection of non-small lung cell cancer in peripheral blood

Michael Mitas, Loretta Hoover, Gerard Silvestri, Carolyn Reed, Mark Green, Andrew T. Turrisi, Carol Sherman, Kaidi Mikhitarian, David J. Cole, Mark I. Block, William E. Gillanders

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

The clinical management of non-small cell lung cancer (NSCLC) would benefit greatly by a test that was able to detect small amounts of NSCLC in the peripheral blood. In this report, we used a novel strategy to enrich tumor cells from the peripheral blood of 24 stage I to IV NSCLC patients and determined expression levels for six cancer-associated genes (lunx, muc1, KS1/4, CEA, CK19, and PSE). Using thresholds established at three standard deviations above the mean observed in 15 normal controls, we observed that lunx (10 of 24, 42%), muc1 (5 of 24, 21%), and CK19 (5 of 24, 21%) were overexpressed in 14 of 24 (58%) peripheral blood samples obtained from NSCLC patients. Patients who overexpressed either KS1/4 (n = 2) or PSE (n = 1) also overexpressed either lunx or muc1. Of patients with presumed curable and resectable stage I to II disease (n = 7), at least one marker was overexpressed in three (43%) patients. In advanced stage III to IV patients (n = 17), at least one marker was overexpressed in 11 patients (65%). These results provide evidence that circulating tumor cells can be detected in NSCLC patients by a high throughput molecular technique. Further studies are needed to determine the clinical relevance of gene overexpression.

Original languageEnglish (US)
Pages (from-to)237-242
Number of pages6
JournalJournal of Molecular Diagnostics
Volume5
Issue number4
DOIs
StatePublished - Nov 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Circulating Neoplastic Cells
Neoplasm Genes
Blood Cells
Genes
Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine

Cite this

Mitas, M., Hoover, L., Silvestri, G., Reed, C., Green, M., Turrisi, A. T., ... Gillanders, W. E. (2003). Lunx is a superior molecular marker for detection of non-small lung cell cancer in peripheral blood. Journal of Molecular Diagnostics, 5(4), 237-242. https://doi.org/10.1016/S1525-1578(10)60480-1

Lunx is a superior molecular marker for detection of non-small lung cell cancer in peripheral blood. / Mitas, Michael; Hoover, Loretta; Silvestri, Gerard; Reed, Carolyn; Green, Mark; Turrisi, Andrew T.; Sherman, Carol; Mikhitarian, Kaidi; Cole, David J.; Block, Mark I.; Gillanders, William E.

In: Journal of Molecular Diagnostics, Vol. 5, No. 4, 11.2003, p. 237-242.

Research output: Contribution to journalArticle

Mitas, M, Hoover, L, Silvestri, G, Reed, C, Green, M, Turrisi, AT, Sherman, C, Mikhitarian, K, Cole, DJ, Block, MI & Gillanders, WE 2003, 'Lunx is a superior molecular marker for detection of non-small lung cell cancer in peripheral blood', Journal of Molecular Diagnostics, vol. 5, no. 4, pp. 237-242. https://doi.org/10.1016/S1525-1578(10)60480-1
Mitas, Michael ; Hoover, Loretta ; Silvestri, Gerard ; Reed, Carolyn ; Green, Mark ; Turrisi, Andrew T. ; Sherman, Carol ; Mikhitarian, Kaidi ; Cole, David J. ; Block, Mark I. ; Gillanders, William E. / Lunx is a superior molecular marker for detection of non-small lung cell cancer in peripheral blood. In: Journal of Molecular Diagnostics. 2003 ; Vol. 5, No. 4. pp. 237-242.
@article{170f815a50744e00a8b5e8d94b9d325b,
title = "Lunx is a superior molecular marker for detection of non-small lung cell cancer in peripheral blood",
abstract = "The clinical management of non-small cell lung cancer (NSCLC) would benefit greatly by a test that was able to detect small amounts of NSCLC in the peripheral blood. In this report, we used a novel strategy to enrich tumor cells from the peripheral blood of 24 stage I to IV NSCLC patients and determined expression levels for six cancer-associated genes (lunx, muc1, KS1/4, CEA, CK19, and PSE). Using thresholds established at three standard deviations above the mean observed in 15 normal controls, we observed that lunx (10 of 24, 42{\%}), muc1 (5 of 24, 21{\%}), and CK19 (5 of 24, 21{\%}) were overexpressed in 14 of 24 (58{\%}) peripheral blood samples obtained from NSCLC patients. Patients who overexpressed either KS1/4 (n = 2) or PSE (n = 1) also overexpressed either lunx or muc1. Of patients with presumed curable and resectable stage I to II disease (n = 7), at least one marker was overexpressed in three (43{\%}) patients. In advanced stage III to IV patients (n = 17), at least one marker was overexpressed in 11 patients (65{\%}). These results provide evidence that circulating tumor cells can be detected in NSCLC patients by a high throughput molecular technique. Further studies are needed to determine the clinical relevance of gene overexpression.",
author = "Michael Mitas and Loretta Hoover and Gerard Silvestri and Carolyn Reed and Mark Green and Turrisi, {Andrew T.} and Carol Sherman and Kaidi Mikhitarian and Cole, {David J.} and Block, {Mark I.} and Gillanders, {William E.}",
year = "2003",
month = "11",
doi = "10.1016/S1525-1578(10)60480-1",
language = "English (US)",
volume = "5",
pages = "237--242",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "4",

}

TY - JOUR

T1 - Lunx is a superior molecular marker for detection of non-small lung cell cancer in peripheral blood

AU - Mitas, Michael

AU - Hoover, Loretta

AU - Silvestri, Gerard

AU - Reed, Carolyn

AU - Green, Mark

AU - Turrisi, Andrew T.

AU - Sherman, Carol

AU - Mikhitarian, Kaidi

AU - Cole, David J.

AU - Block, Mark I.

AU - Gillanders, William E.

PY - 2003/11

Y1 - 2003/11

N2 - The clinical management of non-small cell lung cancer (NSCLC) would benefit greatly by a test that was able to detect small amounts of NSCLC in the peripheral blood. In this report, we used a novel strategy to enrich tumor cells from the peripheral blood of 24 stage I to IV NSCLC patients and determined expression levels for six cancer-associated genes (lunx, muc1, KS1/4, CEA, CK19, and PSE). Using thresholds established at three standard deviations above the mean observed in 15 normal controls, we observed that lunx (10 of 24, 42%), muc1 (5 of 24, 21%), and CK19 (5 of 24, 21%) were overexpressed in 14 of 24 (58%) peripheral blood samples obtained from NSCLC patients. Patients who overexpressed either KS1/4 (n = 2) or PSE (n = 1) also overexpressed either lunx or muc1. Of patients with presumed curable and resectable stage I to II disease (n = 7), at least one marker was overexpressed in three (43%) patients. In advanced stage III to IV patients (n = 17), at least one marker was overexpressed in 11 patients (65%). These results provide evidence that circulating tumor cells can be detected in NSCLC patients by a high throughput molecular technique. Further studies are needed to determine the clinical relevance of gene overexpression.

AB - The clinical management of non-small cell lung cancer (NSCLC) would benefit greatly by a test that was able to detect small amounts of NSCLC in the peripheral blood. In this report, we used a novel strategy to enrich tumor cells from the peripheral blood of 24 stage I to IV NSCLC patients and determined expression levels for six cancer-associated genes (lunx, muc1, KS1/4, CEA, CK19, and PSE). Using thresholds established at three standard deviations above the mean observed in 15 normal controls, we observed that lunx (10 of 24, 42%), muc1 (5 of 24, 21%), and CK19 (5 of 24, 21%) were overexpressed in 14 of 24 (58%) peripheral blood samples obtained from NSCLC patients. Patients who overexpressed either KS1/4 (n = 2) or PSE (n = 1) also overexpressed either lunx or muc1. Of patients with presumed curable and resectable stage I to II disease (n = 7), at least one marker was overexpressed in three (43%) patients. In advanced stage III to IV patients (n = 17), at least one marker was overexpressed in 11 patients (65%). These results provide evidence that circulating tumor cells can be detected in NSCLC patients by a high throughput molecular technique. Further studies are needed to determine the clinical relevance of gene overexpression.

UR - http://www.scopus.com/inward/record.url?scp=10744231667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744231667&partnerID=8YFLogxK

U2 - 10.1016/S1525-1578(10)60480-1

DO - 10.1016/S1525-1578(10)60480-1

M3 - Article

C2 - 14573783

AN - SCOPUS:10744231667

VL - 5

SP - 237

EP - 242

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 4

ER -